Syndax Pharmaceuticals Inc. ( SNDX ) Monday night reported a Q4 net loss attributable to common stockholders of $0.80 per share during the three months ended Dec. 31, 2017, compared with a $0.59 per share net loss during the final three months of 2016 and missing the Capital IQ consensus expecting a net loss of $0.77 per share.
License fee revenue increased to $1.2 million from around $300,000 in fee revenue during the year-ago period, beating the $750,000 Street view.
Syndax finished 2017 with $133.2 million in cash, cash equivalents and short-term investments.
Looking forward, the company is expecting to spend between $18 million to $22 million on research and development during its Q1 ending March 31 and $67 million to $76 million in R&D cost for the full year ending on the next Dec. 31.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
